|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0032743,
umls-concept:C0038952,
umls-concept:C0040405,
umls-concept:C0600558,
umls-concept:C0681842,
umls-concept:C0684249,
umls-concept:C0871261,
umls-concept:C1514888,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2008-9-30
|
|
pubmed:abstractText |
Tumor response is considered a surrogate marker of survival. We investigated whether tumor response based on computed tomography (CT) scan or whole-body [(18)F]fluorodeoxyglucose positron emission tomography (PET) scan after neoadjuvant chemotherapy for resectable non-small-cell lung cancer (NSCLC) is prognostic of survival.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4610-6
|
|
pubmed:dateRevised |
2009-2-26
|
|
pubmed:meshHeading |
pubmed-meshheading:18824709-Antineoplastic Agents,
pubmed-meshheading:18824709-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18824709-Combined Modality Therapy,
pubmed-meshheading:18824709-Female,
pubmed-meshheading:18824709-Fluorodeoxyglucose F18,
pubmed-meshheading:18824709-Humans,
pubmed-meshheading:18824709-Lung Neoplasms,
pubmed-meshheading:18824709-Male,
pubmed-meshheading:18824709-Neoadjuvant Therapy,
pubmed-meshheading:18824709-Positron-Emission Tomography,
pubmed-meshheading:18824709-Predictive Value of Tests,
pubmed-meshheading:18824709-Prognosis,
pubmed-meshheading:18824709-Proportional Hazards Models,
pubmed-meshheading:18824709-Prospective Studies,
pubmed-meshheading:18824709-Radiopharmaceuticals,
pubmed-meshheading:18824709-Statistics, Nonparametric,
pubmed-meshheading:18824709-Survival Rate,
pubmed-meshheading:18824709-Tomography, X-Ray Computed
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
|
|
pubmed:affiliation |
Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. tanvett@moffitt.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
